Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPM Cells for Diabetic Foot Ulcers
NCT06621303Phase 1Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Oct 2024
- Primary completion
- Sep 2025
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OPM cells in diabetic foot ulcer (DFU) and critical limb ischemia (CLI), sponsored by Shanghai East Hospital. Primary endpoint: Incidence of serious adverse reactions at 24 weeks. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
OPM cells
03
Conditions
diabetic foot ulcer (DFU)critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT06621303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06621303.